Table of Contents
Big Pharma is poised for growth due to strong launch portfolios, the availability of high-potential pipeline assets, and companies’ sharpened focus on highperforming markets This report explores and visualizes market dynamics in the Big Pharma peer set out to 2024, using in-house sales forecasts By delving deeper into drivers of strategy, revenue trends, and therapy area focus, this analysis is vital to understanding how the industry will navigate headwinds in order to steer towards robust growth
What’s included in this report:
Therapy Area Analysis
Key questions answered:
What are the significant challenges and drivers facing Big Pharma out to 2024?
Which companies will propel revenue growth over the forecasts period?
Which companies will have leading market share gains and market share losses?
How are late stage pipelines positioned, and what are the most-coveted launch products?
Which therapy areas will experience the largest growth and decline?
What are the portfolio weightings of Big Pharma based on the lifecycle of products?
How is Big Pharma adopting lifecycle management strategies to increase value?
Get Industry Insights. Simply.
Talk to Ahmad
+1 718 618 4302
PharmaPoint: Colorectal Cancer - Global Drug Forecast and Market Analysis to 2025 Summary Colorectal Cancer (CRC) Market, considering the sales of both branded treatments and generic chemotherapy, is expected ...
PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2025 Summary Systemic Lupus Erythematosus (SLE) is a systemic inflammatory autoimmune disease ...
PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2025 Summary Ulcerative Colitis (UC) is a type of chronic IBD that causes inflammation and ulcers in the innermost lining of ...